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Development of an orally available 
inhibitor of CLK1 for skipping 
a mutated dystrophin exon in 
Duchenne muscular dystrophy
Yukiya Sako1, Kensuke Ninomiya1, Yukiko Okuno2, Masayasu Toyomoto1, Atsushi Nishida3, 
Yuka Koike1,†, Kenji Ohe1, Isao Kii1,†, Suguru Yoshida4, Naohiro Hashimoto5, 
Takamitsu Hosoya4, Masafumi Matsuo3 & Masatoshi Hagiwara1
Duchenne muscular dystrophy (DMD) is a fatal progressive muscle-wasting disease. Various attempts 
are underway to convert severe DMD to a milder phenotype by modulating the splicing of the 
dystrophin gene and restoring its expression. In our previous study, we reported TG003, an inhibitor 
of CDC2-like kinase 1 (CLK1), as a splice-modifying compound for exon-skipping therapy; however, its 
metabolically unstable feature hinders clinical application. Here, we show an orally available inhibitor 
of CLK1, named TG693, which promoted the skipping of the endogenous mutated exon 31 in DMD 
patient-derived cells and increased the production of the functional exon 31-skipped dystrophin 
protein. Oral administration of TG693 to mice inhibited the phosphorylation of serine/arginine-rich 
proteins, which are the substrates of CLK1, and modulated pre-mRNA splicing in the skeletal muscle. 
Thus, TG693 is a splicing modulator for the mutated exon 31 of the dystrophin gene in vivo, possibly 
possessing therapeutic potential for DMD patients.
Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder that affects approxi-
mately 1 out of 3,500 newborn boys, and the most prevalent fatal muscle-wasting disease1–3. It is characterized by 
progressive muscle deterioration and wasting due to the absence of dystrophin3. Unfortunately, DMD patients 
usually succumb to cardiac or respiratory failure attributed to muscle dysfunction in their 20s, and no effective 
cure is currently available. Nonsense mutations or deletions of exons, which cause frame shifts in the dystrophin 
mRNA and generate premature termination codons (PTCs), usually result in the lack of dystrophin protein and 
development of the disease.
Current therapeutic attempts to restore dystrophin protein expression include the induction of exon 
skipping with antisense oligonucleotides (AONs)4–7 or small molecules (TG003)8 and the suppression of 
nonsense-mediated mRNA decay, which includes the read-through of PTC (e.g. Ataluren)9,10, by chemical com-
pounds. Several AONs have been designed as exon-skipping therapies, in which ribosomes “skip” the mutated 
exons in pre-mRNA transcripts to produce an in-frame, but truncated, transcript that is translated into a func-
tional dystrophin protein11–13. However, considering their therapeutic cost and delivery efficiency to muscles, 
small chemical compounds with exon-skipping function are highly anticipated for DMD therapy.
We previously reported on the small molecule TG003 that promotes skipping of dystrophin exon 31 in cells 
harboring the c.4303G > T mutation8. In the patient’s muscle cells, two dystrophin mRNA transcripts of differ-
ent lengths are detected in nearly equal amounts—one with the premature TAG termination codon in exon 31, 
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and the other lacking only exon 31. The dystrophin mRNA lacking the 111-bp exon 31 is in-frame to produce 
an internally deleted, but functional dystrophin protein. The expression of the functional truncated protein is 
enhanced by TG003 treatment.
Our initial findings showed that TG003 is an inhibitor of CDC-like-kinases (CLKs; CLK1, 2, 4)14, which phos-
phorylate stretches of alternating serine and arginine residues in serine/arginine-rich (SR) protein family mem-
bers15,16. CLK-dependent phosphorylation of SR proteins induces their association with transcribed RNAs17–19 
to promote or, in some cases, repress splice-site recognition, resulting in alternative splicing20–22. Thus, TG003 
modifies mRNA splicing by inhibiting the phosphorylation of SR proteins14,23,24.
Pharmacological efficacy in target tissues is an unavoidable issue for developing therapeutic modalities. While 
TG003 was effective in modulating CLK activity and mRNA splicing in cellular models of DMD8, its metabolic 
instability hinders its clinical application. In this study, we identified an orally available selective CLK1 inhibitor, 
TG693, which promoted exon skipping and production of a truncated functional dystrophin protein in immor-
talized cells derived from a patient with DMD (c.4303G > T) to the same extent as TG003. Additionally, TG693 
was metabolically stable and transiently detected in the skeletal muscle at a bioactive level, supporting its thera-
peutic potential as an orally available drug candidate.
Results
Development of the metabolically stable CLK1 inhibitor TG693. We screened for stable exon-skip-
ping inducers of the mutant DMD exon 31 (c.4303G > T) in our original chemical library and identified the small 
molecule 5-(4-pyridinyl)-1H-indazole (henceforth referred to as TG693) as an exon-skipping inducer (Fig. 1a). 
To test the in vivo stability of TG003 and TG693, mice were administered a single subcutaneous injection of either 
compound and then serum concentrations were monitored by liquid chromatography-mass spectrometry (LC/
MS) at serial time points. While only trace amounts of TG003 were detected, the average TG693 serum concen-
tration was 13 μ M at 6 h post-injection, indicating that TG693 was more stable than TG003 in the blood plasma 
(Fig. 1b). Subsequent analyses on CLK1 inhibition with in vitro kinase assays revealed that TG693 inhibited the 
phosphorylation of a synthetic SRSF1 RS domain peptide with a half-maximal inhibitory concentration (IC50) 
of 112.6 nM, approximately 10-fold weaker than that of TG003 (IC50 = 13.1 nM) (Fig. 1c). We also examined 
whether TG693 served as an ATP-competitive inhibitor. Hanes-Woolf plots showed parallel lines with y-inter-
cepts that correspond to TG693 concentration, demonstrating that TG693 competes with ATP for a single site in 
CLK1 (Fig. 1d; Km = 14.88 μ M, KI = 105.3 nM). Moreover, kinetic parameters (Kmapparent, Vmaxapparent, α , α ’) were 
determined by Michaelis-Menten model fitting (Supplementary Table S1), which indicated that TG693 was an 
ATP-competitive type I inhibitor that antagonized CLK1. Further, in order to evaluate the specificity of TG693-
mediated kinase, we investigated the in vitro inhibitory activity of 1 μ M TG693 against a panel of 313 recombinant 
kinases. TG693 inhibited CLK1 and Haspin activity by over 90% and kinases over 50% inhibition were shown in 
a kinase dendrogram (Fig. 1e). These suggested that TG693 was a potent and selective inhibitor of CLK1.
TG693 inhibits CLK1 kinase activity in cells. TG003 administration to cultured cells inhibits the 
CLK1-mediated phosphorylation of SR proteins, particularly that of SRSF417. To examine the cellular activity 
of TG693, HeLa cells were treated with increasing concentrations of compounds, and then SR protein phos-
phorylation was assessed by western blotting with an anti-pan-phospho-SR antibody that recognizes canonical 
SR protein family members25. Notably, TG693 and TG003 inhibited the phosphorylation of SRSF4 at 5 μ M and 
SRSF6 at 20 μ M and 10 μ M, respectively (Fig. 2a), confirming that these compounds act via the same biochemical 
mechanism.
TG693 induces exon-skipping of a DMD splicing reporter. Since TG693 was shown to be a metabol-
ically stable CLK1 inhibitor, we evaluated the dose-dependent effects of TG693 on the skipping of mutant DMD 
exon 31 (c.4303G > T) with HeLa cells expressing a H492-Dys Ex31m splicing reporter8. Interestingly, the effects 
of TG693 and TG003 on the exon-skipping were comparable, despite their differences in suppressing CLK1 activ-
ity in in vitro kinase assays (Fig. 2b, upper panel); and TG693 had no effect on wild type transcript splicing even 
at 30 μ M (Fig. 2c). To determine if this activity was specific to exon 31 mutation, we then evaluated the function 
of TG693 on exon-skipping with the H492-dysEx27m splicing reporter containing a point deletion in exon 27 
(c.3613delG (p.Glu1205LysfsX9)) that causes a frameshift-induced premature termination codon. As shown in 
Supplementary Fig. S1, TG693 induced exon 27-skipping from H492-dysEx27m reporter, similar to that previ-
ously observed with TG0038.
CLK1 pre-mRNA splicing is regulated by CLK1 kinase activity14. In this mechanism, abundant CLK1 levels 
induce SR phosphorylation, resulting in the removal of exon 4 from CLK1 pre-mRNA and nonsense-mediated 
mRNA decay26,27. In previous reports, administration of TG003 to cultured cells promoted full-length CLK1 
expression14,17. Consistently, CLK1 exon 4-skipped transcript expression was attenuated in the presence of 5 μ 
M TG693 (Fig. 2b, middle panel), suggesting that TG693 exhibited a considerable inhibitory effect on CLK1 and 
concomitant exon-skipping, similar to that of TG0038.
TG693 restored dystrophin expression in patient-derived cells. We previously reported that TG003 
restored dystrophin production in patient-derived myotubes8. Therefore, we investigated the effect of TG693 
on dystrophin expression in an immortalized cell line derived from a DMD patient with the c.4303G > T muta-
tion, which was by established by the forced expression of constitutively active cyclin-dependent kinase 4, cyclin 
D1, and telomerase28,29. Notably, TG693 promoted the skipping of mutant exon 31 (Fig. 3a), but did not affect 
any other exons (Supplementary Fig. S2 and Table S4). Moreover, TG693 was sufficient to increase dystrophin 
protein expression in a dose-dependent manner with a 130% and 200% increase at 10 and 20 μ M, respectively 
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Figure 1. TG693 is a metabolically stable CDC2-like kinase 1 (CLK1) inhibitor. (a) TG693 and TG003 
chemical structures. (b) Pharmacokinetic profile of TG693 after a single 30 mg kg−1 dose administered by 
subcutaneous injection in imprinting control region (ICR) mice. Data indicate the mean ± SEM (n = 3). (c) 
Recombinant CLK1 was incubated with the substrate peptide in the presence of the indicated concentrations of 
small molecules. Data represent the means ± SD (n = 3). Representative dose-response curves with Hill slopes 
are shown. (d) TG693 competitive ATP inhibition is shown in Michaelis-Menten (left) and Hanes-Woolf (right) 
plots. CLK1 kinase activity was measured at the indicated concentrations of TG693 and ATP. Velocity was 
plotted versus [ATP] and [ATP]/velocity was plotted versus [ATP]. (e) Map of the inhibitory activities of TG693 
on a kinase dendrogram. Percent inhibition by 1 μ M TG693 was measured for a panel of 313 kinases. Red circles 
indicate the inhibited kinases and are sized according to percent inhibition. The illustration was reproduced 
courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
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Figure 2. TG693 promotes skipping of mutated exon 31 in HeLa cells in a dose-dependent manner. (a) SR 
protein phosphorylation was assessed in HeLa cells treated with TG693 and TG003 for 1 h. Lamin B served 
as a loading control. Uncropped images have been provided in Supplementary Fig. S4. (b,c) Effect of TG693 
on exon 31 skipping with the reporter plasmid. Transfected HeLa cells were incubated in the presence of 
TG693, TG003, or DMSO vehicle for 24 h. Reporter and endogenous CLK1 splicing was then analyzed by RT-
PCR. GAPDH served as a control. The Splicing ratios were quantified by intensity analysis and normalized to 
GAPDH expression. Uncropped images have been provided in Supplementary Figs S5 and S6, respectively. Data 
represent the means ± SD (n = 3).
Figure 3. TG693 induces truncated dystrophin protein expression in patient-derived cells. Immortalized 
DMD patient-derived cells were treated with increasing concentrations of TG693 for 2 d. (a) Semi-quantitative 
RT-PCR for dystrophin exon skipping. The uncropped image is provided in Supplementary Fig. S7. Data 
represent the means ± SD (n = 3). *p < 0.05. (b) Western blotting of dystrophin protein expression in TG693-
treated cells using C-terminal-directed antibody. α -Tubulin was used as a loading control. Uncropped images 
have been provided in Supplementary Fig. S8. Data are representative of three independent experiments.
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(Fig. 3b). Thus, these results supported the therapeutic potential for TG693 in DMD patient cells harboring the 
c.4303G > T mutation in dystrophin exon 31.
Oral administration of TG693 modulated splicing in mouse skeletal muscle. To analyze the in vivo 
effects of TG693, mice were orally administered TG693 (30 mg kg−1). Notably, a significant amount of TG693 (> 
4 μ M) was detected in the tibialis anterior (TA) muscle of mice (Fig. 4a), as well as a marked concomitant reduc-
tion of SR protein phosphorylation, particularly that of SRSF4 (Fig. 4b). Further analysis of splicing modulation 
showed that TG693 promoted full-length Clk1 transcript expression in TA, suggesting that treatment suppressed 
the excision of exon 4 induced by CLK1 activity (Fig. 4c). TG693 was active in other muscle tissues, such as the 
heart and diaphragm, as well as skeletal muscle (Fig. 4d). We also confirmed that TG693 had no apparent toxicity 
in rats at up to 100 mg kg−1 per os (Supplementary Fig. S3). No mortalities or gross abnormalities were observed 
in TG693-treated animals during the experimental period, nor did it affect body weight in mice administrated an 
overdose of the compound. Thus, these results suggest that TG693 is a useful tool for inhibition of CLK1 activity 
in vivo per os.
Discussion
We succeeded in identifying a selective ATP-competitive inhibitor of CLK1, named TG693. TG693 is structurally 
distinct from TG003 (Fig. 1a), but it similarly shows potent CLK1 inhibition as well as dystrophin exon 31 skip-
ping enhancement in cells (Fig. 2a and b), strengthening our original hypothesis that CLK1 can be the molecular 
target for splicing manipulation8,14. TG693 restored the dystrophin protein expression in cells harboring a point 
mutation (c.4303G > T) in exon 31 of the dystrophin gene by inducing exon-skipping (Fig. 3). The c.4303G > T 
point mutation in exon 31 attenuates exon recognition by disruption and creation of splicing elements such 
as exonic splicing enhancer and silencer8,30,31. Thus, mutated exon 31 is targeted by TG693 to suppress exon 
recognition without altering wild type transcript splicing (Fig. 2c). We also showed TG693 promotes skipping 
of a mutated exon 27 in another patient (Supplementary Fig. S1). In vivo mouse experiments revealed that oral 
TG693 administration decreased SR protein phosphorylation in muscle tissue and modulated the splicing pat-
tern of endogenous Clk1 (Fig. 4). Thus, these results indicated that TG693 could modulate the splicing pattern 
of the mutated dystrophin gene in the patient by oral administration. This represents a significant advance in 
drug-induced exon skipping therapy for DMD.
Splicing modulation has drawn increasing attention as a therapeutic strategy for DMD. In 2016, two antisense 
drugs that modulate splicing were approved by the U.S. Food and Drug Administration (FDA) (e.g. Eteplirsen 
and Nusinersen), and exon-skipping therapy has become a reality. While AONs offer a specific way to modulate 
splicing in a therapeutic manner, some hurdles must be overcome for the orally available antisense drugs32,33. 
Compared to AONs, small chemical compounds may not be as specific, but more advantageous for the synthesis 
cost and the oral availability. Thus, splicing modulation with small molecules can become an alternative therapeu-
tic approach in addition to AONs, and can expand applications of splicing modulation therapy.
Figure 4. TG693 effect as a CLK1 inhibitor in the mouse tibialis anterior muscle. (a) TG693 bioavailability 
in the tibialis anterior (TA) muscle of ICR mice after oral administration of a single 30 mg kg−1 dose. Data 
represent the mean ± SEM (n = 3). (b) SR protein phosphorylation status in the TA muscle of ICR mice 
after oral administration. Lamin B served as a loading control. SRSF4 phosphorylation was quantified 
by densitometry. Uncropped images are provided in Supplementary Fig. S9. Data represent means ± SD 
(n = 5). *p < 0.05. (c,d) Clk1 expression in the TA muscle, heart and diaphragm were analyzed by RT-
PCR with a GAPDH internal control. Uncropped images are provided in Supplementary Fig. S10 and in 
Supplementary Fig. S11, respectively. Data represent the means ± SD (n = 3). *p < 0.05.
www.nature.com/scientificreports/
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CLK1 inhibitors have attracted extensive attention in recent years. Notably, TG693 is the first and only CLK1 
inhibitor which is orally available and metabolically stable in blood34,35. As such, we believe that the present study 
will provide a foundation for the continued development of therapies other diseases associated with aberrant 
CLK1 activity—such as Alzheimer’s and Influenza36,37.
Our results show that TG693 mediated CLK1 inhibition elicits changes in SR protein phosphorylation, par-
ticularly that of SRSF4 and SRSF6 (Figs 2a and 4b). SR proteins regulate a multitude of splicing events in the 
phosphorylation dependent manner21, raising the possibility that reduction of SR proteins phosphorylation 
may cause off-target splicing alteration. Therefore, we previously checked transcriptional wide effect of TG003, 
which similarly inhibits phosphorylation of SR proteins as TG693 in vitro (Fig. 2a), and we found that only 0.3% 
(110/37487)24 of registered alternative splicing events were skipped enhanced by TG003. TG693 is fairly specific 
in its inhibition profile, showing significant off target effects (> 70%) to only 4 of 313 kinases (Fig. 1e). This solid-
ifies the mode-of-action evidence for TG693. Although we confirmed TG693 had no apparent acute toxicity in 
rats at up to 100 mg kg−1 per os (Supplementary Fig. S3), more preclinical studies with other animal models are 
necessary to consider the clinical application of TG693. We have also started a project to seek next generation 
CLK1 inhibitors with a pharmaceutical company to improve the efficacy and selectivity of TG693 based on the 
information written here.
TG693 is a simple compound with indazole and pyridine groups (Fig. 1a) far more metabolically stable than 
TG003 which is a benzothiazole compound. We believe that TG003 is easily metabolized via O-demethylation 
and subsequent sulfate conjugation of the hydroxyl group38 and likely interacts with CLK1 via hydrogen bonds 
in the ATP-binding pocket39. In the case of TG693, metabolically stable indazole moiety is suspected to form a 
hydrogen bond with an amino acid residues of CLK140, but structural studies will be necessary to confirm this 
hypothesis.
Our results suggest that exon-skipping therapy with orally available small molecule has therapeutic potential 
to genetic diseases caused by disruption/creation of splicing elements, including Duchenne muscular dystrophy. 
We believe that our approach is potentially applicable to other genetic diseases caused by nonsense or frameshift 
mutations in the internal coding exons whose length is a multiple of three. On this criteria, we found 6,244 
pathogenic mutations in the NIH ClinVar database that may be target candidates for exon-skipping therapy with 
TG693. Our efforts have focused on expanding application of TG693 to other diseases, addition to the Duchenne 
muscular dystrophy.
Methods
Materials. TG693 was synthesized as detailed in the Supporting Information. TG003 was prepared as 
described previously14. Both compounds were dissolved in dimethylsulfoxide (DMSO) (Hybri-MAXTM, Sigma-
Aldrich, St. Louis, MO, USA). Carboxymethyl cellulose sodium salt was obtained from Nacalai Tesque (Kyoto, 
Japan).
Antibodies. The source and catalog numbers of commercially available primary antibodies have been pro-
vided in Supplemental Table 2. Mouse monoclonal antibodies against phospho-SR proteins (1H4) and α -tubulin 
(DM1A) were purchased from Invitrogen (Carlsbad, CA, USA) and Thermo Fisher Scientific (Yokohama, Japan), 
respectively. Rabbit polyclonal antibody against dystrophin was obtained from Abcam (Cambridge, UK). Goat 
polyclonal antibody against Lamin B (M-20) was purchased from Santa Cruz Biotechnology (Santa Cruz, Dallas, 
TX, USA). HRP-conjugated anti-rabbit, anti-goat IgG, and anti-mouse IgG secondary antibodies were purchased 
from GE Healthcare Life Sciences (Pittsburgh, PA, USA), Jackson ImmunoResearch (West Grove, PA, USA), and 
Abcam, respectively.
In vitro kinase assay. CLK1 kinase activity was assessed as previously reported14 with minor modifications. 
The reaction mixture containing serially diluted inhibitors, 10 mM MOPS-KOH (pH 6.5), 10 mM magnesium 
chloride, 200 μ M EDTA, 1 μ M ATP, 0.167 μ Ci of [γ -32P] ATP, 0.417 μ g of synthetic RS peptide, and recombinant 
GST-tagged human CLK1 (Cat #04–126, Carna Biosciences, Kobe, Japan) was prepared in a final volume of 25 μ 
L. The reaction mixture was incubated at 30 °C for 30 min, and phosphoric acid was added at a final concentra-
tion of 5% to stop the reaction. Then, 25 μ L of the reaction mixture was dispensed on a P81 phosphocellulose 
membrane (Cat #20-134, Merck Millipore, Darmstadt, Germany) and washed four times in 5% phosphoric acid. 
Cherenkov light from the incorporated 32P was measured using a liquid scintillation counter. The kinase assay 
conditions, including the incubation period and concentrations of kinases and substrates, were optimized to 
maintain linearity during incubation. The net radioactivity was determined by subtracting the background count 
from the reaction mixture without kinases. The IC50 of each compound was calculated by interpolation on a 
log-concentration-response curve fitted with a four-parameter logistic equation.
Kinase profiling. The effect of 1 μ M TG693 on 313 kinases (listed in Supplementary Table S2) was examined 
with immobilized metal ion affinity-based fluorescence polarization (IMAP) assay or off-chip mobility shift assay 
(MSA) depending on the kinase being examined with an ATP concentration at the Km or 1 mM. These assays rely 
on the phosphorylation of small synthetic peptides developed for each kinase, and detect activity by changes in 
electrophoretic mobility (MSA assay) or by binding of a fluorescently labelled peptide to a large micro-particle 
and concomitant polarization increases (IMAP assay). Reaction conditions for each kinase are described in 
Supplementary Table S5. All kinase assays were carried out at Carna Biosciences (Kobe, Japan). The inhibitory 
map was constructed using Kinome Render41.
Immobilized metal ion affinity-based fluorescence polarization (IMAP) Assay. Substrate/ATP/
metal (4× ) and kinase (2× ) solutions were prepared using with assay buffer (20 mM HEPES, 0.01% Tween-20, 
2 mM DTT, pH 7.4), and then mixed in 384-well black plates for 1 hour at room temperature. IMAP binding 
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solution (IMAP Screening Express kit; Molecular Devices, Sunnyvale, CA, USA) was added to each well and 
incubated for 30 min. The level of kinase activity was then evaluated by fluorescence polarization at 485/530 nm 
(Ex/Em).
Off-Chip Mobility Shift Assay (MSA). Inhibitor (4× ), substrate/ATP-Metal (4× ), and kinase (2× ) solu-
tions were prepared with assay buffer (20 mM HEPES, 0.01% Triton X-100, 2 mM DTT, pH 7.5) and mixed in 
384-well plates at room temperature for 1 or 5 h depending on the kinase. Reactions were stopped by the addition 
of termination buffer (QuickScout Screening Assist MSA; Carna Biosciences). The entire reaction mixture was 
then applied to a LabChip system (Perkin-Elmer, Waltham, MA, USA) and the product and substrate peptide 
peaks were separated and quantified, and then heights of product (P) and substrate (S) peptide peaks were calcu-
lated. The level of kinase activity was evaluated with the following equation: activity = P/(P + S).
ATP kinetics assay. Kinetic reactions were performed with the same method used for in vitro kinase assays, 
except that 0.05–0.4 μ Ci of [γ -32P] ATP was used. Km and Ki values were calculated with a competitive inhibition 
model in Prism 6 software (GraphPad Software, San Diego, CA, USA).
Plasmid construction, cell culture, and transfection. The H492-dys Ex31m, H492-dys Ex31w, and 
H492-dys Ex27m plasmids were prepared as described previously8. HeLa cells were maintained in low-glucose 
Dulbecco’s modified Eagle’s medium (Nacalai Tesque) supplemented with 10% fetal bovine serum, 100 U/
mL penicillin, and 100 μ g/mL streptomycin. Immortalized muscle cells (D4P4) from a DMD patient with the 
c.4303G > T mutation were established as described previously28. Cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (Wako Pure Chemical Industries, Osaka, Japan) supplemented with 20% fetal bovine 
serum (Gibco, Grand Island, NY, USA), 2% Ultroser™ G serum substitute (Pall Corp., NY, USA), and 1% 
antibiotic-antimycotic solution (Gibco). Transfections were carried out using Lipofectamine 2000 (Thermo 
Fisher Scientific) following the manufacturer’s instructions. For reporter assays, TG693 and TG003 were added 
to the culture medium for 24 h before analysis.
RNA Isolation and Semiquantitative RT-PCR. Total RNA was isolated from HeLa cells in 800 μ L 
Sepasol-RNA I Super G (Nacalai Tesque) and then treated with RQ1 RNase-free DNase (Promega, Madison, 
Wisconsin, USA) according to the manufacturer’s protocol. DMD patient-derived cells were lysed in 800 μ L 
Trizol reagent (Thermo Fisher Scientific) and then RNA was isolated with a Direct-zol RNA MiniPrep kit (Zymo 
Research, Irvine, CA, USA). Tibialis anterior (TA) muscle homogenates were prepared using a mortar and then 
RNA was isolated with an RNeasy MiniPrep kit (Qiagen, Hilgen, Germany). First-strand cDNA was synthesized 
using Superscript II reverse transcriptase (Invitrogen) and random hexamers (Takara Bio, Inc., Shiga, Japan). 
Semi-quantitative RT-PCR was performed with Ex Taq polymerase (Takara Bio, Inc.) with the following cycle 
conditions: 95 °C for 2 min, followed by 32 (reporter and Clk1) or 25 cycles (GAPDH) of denaturation at 95 °C 
for 20 s, annealing at 58 °C for 20 s, and elongation at 72 °C for 1 min, with a final 5 min incubation at 72 °C in 
a PCR thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA). PCR products were separated by electro-
phoresis and stained with ethidium bromide. Images were obtained with a ChemiDocTM MP Imaging System 
(Bio-Rad) and analyzed with Image Lab software (Bio-Rad). Skipping efficiencies were determined by quantifying 
the skipped products with a DNA 1000 LabChip Kit on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA). Exon skip/inclusion ratios were calculated as the amount of skipped transcript relative to the 
sum the full-length and skipped transcript. The primers for semi-quantitative RT-PCR were as follows: human 
CLK1 forward, 5′ -ATG AGA CAC TCA AAG AGA ACT TAC TG-3′ ; human CLK1 reverse, 5′ -CTT TAT GAT 
CGA TGC ACT CCA C-3′ ; mouse Clk1 forward, 5′ -ATG AGA CAT TCA AAG AGA ACT TAC TG-3′ ; mouse 
Clk1 reverse, 5′ -CAC TTT ATG ATC GAT GCA TTC C-3′ ; GAPDH forward, 5′ -CCA TCA CCA TCT TCC 
AGG AGC GAG-3′ ; GAPDH reverse, 5′ -GTG ATG GCA TGG ACT GTG GTC ATG-3′ ; dystrophin forward, 5′ 
-CCT GTA GCA CAA GAG GCC TTA-3′ ; dystrophin reverse, 5′ -TCC ACA CTC TTT GTT TCC AAT G-3′ ; 
DMD splicing reporter forward, 5′ -ATT ACT CGC TCA GAA GCT GTG TTG C-3′ ; and DMD splicing reporter 
reverse, 5′ -AAG TCT CTC ACT TAG CAA CTG GCA G-3′ .
Western blot analysis. Proteins were extracted from HeLa cells, immortalized DMD cells, and mouse 
muscle tissue using CelLytic M (Sigma-Aldrich, St. Louis, MO, USA), 1× Cell Lysis Buffer (Cell Signaling 
Technology, Danvers, MA, USA), and CelLytic MT (Sigma-Aldrich), respectively. All buffers were supplemented 
with protease and phosphatase inhibitor cocktail (#25955 and #0757461, Nacalai). Protein concentrations were 
quantified with Protein Assay Reagent (Pierce by Thermo Fisher Scientific). The HeLa cell and mouse tissue 
lysates were mixed with Sample buffer (#0949914, Nacalai), denatured at 95 °C for 5 min, and then electro-
phoresed in a 10% SuperSepTM Ace gel (Wako). The lysates of immortalized cells were mixed with NuPAGE 
LDS Sample buffer (Thermo Scientific Fisher), denatured at 70 °C for 10 min, and electrophoresed in a 3–8% 
NuPAGE Novex Tris-Acetate gels (Thermo Scientific Fisher). The samples were then transferred to PVDF 
membranes (Pall Corporation, Port Washington, NY, USA). Antibody reactions were performed with Can Get 
Signal® Immunoreaction Enhancer Solution (Toyobo, Osaka, Japan). Peroxidase activities were visualized with 
ImmunoStar® LD (Wako) and a ChemiDocTM MP Imaging System (Bio-Rad).
Mice and TG693/TG003 administration. Seven-week-old, male Jcl:TCR mice were obtained from 
Charles River Laboratories (Shiga, Japan). All procedures were performed in accordance with the US National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal 
Care and Use Committee of Kyoto University Graduate School of Medicine. Mice were subcutaneously injected 
with 30 mg kg−1 TG693 or TG003 suspended in 5% DMSO, 5% Solutol, 9% Tween-80, and 81% saline. TG693 was 
also administered orally at a dose of 30 mg kg−1 suspended in 0.5% carboxymethylcellulose.
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In vivo pharmacokinetic analysis. TG693 metabolism and tissue bioavailability were assessed in mouse 
plasma and muscle tissue. To collect plasma, mice were anesthetized with isoflurane (Mylan, Osaka, Japan) at 
the indicated time point. Whole blood samples were collected, allowed to clot, and then centrifuged to isolate 
serum. TG693 or TG003 serum levels were analyzed by LC/MS with an Agilent 6420 Q-TOF mass spectrome-
ter (Agilent Technologies) and ZORBAX HILIC Plus (TG693) or ZORBAX Eclipse Plus C18 (TG003) columns 
(Agilent Technologies). For muscle tissue bioavailability, mice were sacrificed by cervical dislocation and the 
tibialis anterior (TA) muscles, heart, and diaphragm dissected. TA homogenates were prepared using a Bead 
Crusher μ T-12 shaking machine (Taitec, Kyoto, Japan) in saline and used to assess TG693 levels by LC/MS with a 
Poroshell 120 PFP (Agilent Technologies).
Statistical analysis. Statistical analysis was performed using Student’s t-tests, except for the comparison 
of exon-skipping ratio in patient-derived cells analyzed by one-way ANOVA with independent post hoc Tukey’s 
multiple comparison testing. Results are reported as the means ± SD. Statistical significance was defined as 
p < 0.05. IC50 values were calculated from data fitted to a four-parameter logistic curve (variable slope) in Prism 
6.0 software.
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